SARTORIUS AG SARTORIUS PREF SHS (0NIR)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 260.60 |
|---|---|
| 52-week range | 198.06 – 271.67 |
| Return, 1 month / 3 months | +5.8% / +19.3% |
| Return, 1 year / 3 years | +14.0% / +12.5% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -22.5% |
| Average daily value traded | 5.51M EUR |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sartorius is a German supplier of laboratory and bioprocess equipment. Its laboratory products business provides balances, pipettes, water purification systems and other instruments used in research and quality-control labs. Its bioprocess solutions business supplies single-use bags, filters, tubing and fermentation equipment to makers of biopharmaceuticals, helping them grow cells and purify medicines. Customers include pharmaceutical companies, contract manufacturers, research institutes and university laboratories, and the company is based in Göttingen, Germany.
SARTORIUS AG SARTORIUS PREF SHS trades under the code 0NIR on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
SARTORIUS AG SARTORIUS PREF SHS (0NIR) trades on the London Exchange in UK. It last closed at EUR 260.60 on 19 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 963 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.0% and over the last three months it rose 19.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 11.3% | ||
| From 52-week high | -1.8% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 19.3% | ||
| 6-month return | 7.0% | ||
| 12-month return, skipping the last month | 7.7% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.5% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 5.51M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 39 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.8% |
|---|---|
| 1 month | +5.8% |
| 3 months | +19.3% |
| 6 months | +7.0% |
| 1 year | +14.0% |
| 3 years | +12.5% |
| 5 years | −50.5% |
Signals
| 50-day / 200-day average | 246.96 / 234.04 |
|---|---|
| Golden / death cross (60 days) | Golden, 34 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.23 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 0.7400 |
| 28 Mar 2025 | EUR 0.7400 |
| 2 Apr 2024 | EUR 0.7400 |
| 30 Mar 2023 | EUR 1.4400 |
| 28 Mar 2022 | EUR 1.2600 |
| 29 Mar 2021 | EUR 0.7100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.